Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMEB
2009-012607-26Phase 2Completed
- Sponsor
- University of Cologne
- Start
- Sep 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by University of Cologne. Primary endpoints: Accuracy of FDG-/FLT-PET for early prediction of non-progression, Accuracy of DCE-MRI for early prediction of non-progression and 7 more. Started Sep 2009; status: completed.
02
Drugs
erlotinibbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-012607-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012607-26.